|8.13||-0.1400||-1.69%||Vol 2.01M||1Y Perf -47.29%|
|Aug 9th, 2022 16:00 DELAYED|
|- -||-0.04 -0.49%|
|Target Price||23.81||Analyst Rating||Strong Buy 1.25|
|Potential %||192.87||Finscreener Ranking||★★★★+ 57.64|
|Insiders Trans % 3/6/12 mo.||-/-43/-85||Value Ranking||★★★★ 55.58|
|Insiders Value % 3/6/12 mo.||-/-39/-99||Growth Ranking||★★★★+ 66.15|
|Insiders Shares Cnt. % 3/6/12 mo.||-/-35/-98||Income Ranking||— -|
|Price Range Ratio 52W %||1.64||Earnings Rating||Sell|
|Market Cap||1.04B||Earnings Date||4th Aug 2022|
Today's Price Range
5 Year PE Ratio Range
|Moving Averages:||Strong Sell|
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||-|
|Estimated EPS Next Report||-0.22|
|EPS Growth Next 5 Years %||-|
|Avg. Weekly Volume||3.64M|
|Avg. Monthly Volume||3.03M|
|Avg. Quarterly Volume||2.88M|
Aurinia Pharmaceuticals Inc (NASDAQ: AUPH) stock closed at 8.27 per share at the end of the most recent trading day (a -1.19% change compared to the prior day closing price) with a volume of 3.16M shares and market capitalization of 1.04B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 294 people. Aurinia Pharmaceuticals Inc CEO is Peter S. Greenleaf.
The one-year performance of Aurinia Pharmaceuticals Inc stock is -47.29%, while year-to-date (YTD) performance is -63.84%. AUPH stock has a five-year performance of 38.99%. Its 52-week range is between 7.7 and 33.9715, which gives AUPH stock a 52-week price range ratio of 1.64%
Aurinia Pharmaceuticals Inc currently has a PE ratio of -8.20, a price-to-book (PB) ratio of 3.32, a price-to-sale (PS) ratio of 23.65, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -37.35%, a ROC of -40.34% and a ROE of -42.17%. The company’s profit margin is -%, its EBITDA margin is -248.60%, and its revenue ttm is $59.70 Million , which makes it $0.42 revenue per share.
Of the last four earnings reports from Aurinia Pharmaceuticals Inc, there were 1 positive earnings surprise and 3 negative earnings surprise. The company has EPS estimate of $-0.22 for the next earnings report. Aurinia Pharmaceuticals Inc’s next earnings report date is -.
The consensus rating of Wall Street analysts for Aurinia Pharmaceuticals Inc is Strong Buy (1.25), with a target price of $23.81, which is +192.87% compared to the current price. The earnings rating for Aurinia Pharmaceuticals Inc stock is Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Aurinia Pharmaceuticals Inc has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Aurinia Pharmaceuticals Inc has a Sell technical analysis rating based on Technical Indicators (ADX : 13.54, ATR14 : 0.85, CCI20 : -77.09, Chaikin Money Flow : -0.05, MACD : -0.73, Money Flow Index : 40.03, ROC : -21.31, RSI : 27.64, STOCH (14,3) : 17.38, STOCH RSI : 0.24, UO : 42.52, Williams %R : -82.62), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Aurinia Pharmaceuticals Inc in the last 12-months were: David R.W. Jayne (Option Excercise at a value of $36 200), George M. Milne (Buy at a value of $54 100), George Mclean Milne (Buy at a value of $54 100), Jill D. Leversage (Buy at a value of $32 064), Joseph P. Hagan (Option Excercise at a value of $203 200), Joseph P. Hagan (Sold 40 000 shares of value $903 650 ), Massimilano Colao (Sold 3 205 shares of value $38 492 ), Matthew Donley (Sold 3 052 shares of value $36 655 ), Michael R. Martin (Option Excercise at a value of $1 985 520), Michael R. Martin (Sold 504 849 shares of value $12 634 953 ), Neil Solomons (Option Excercise at a value of $1 831 700), Neil Solomons (Sold 454 846 shares of value $12 045 550 ), R. Hector Mackay-Dunn (Buy at a value of $54 985), Robert Huizinga (Option Excercise at a value of $381 715), Robert Huizinga (Sold 199 849 shares of value $5 384 945 )
Wed, 27 Jul 2022 03:29 GMT Aurinia Pharmaceuticals (AUPH) Receives a Buy from SVB Securities- TipRanks. All rights reserved.
Thu, 12 May 2022 23:44 GMT Aurinia Stock: Analyst Gets a Bit More Cautious, but Still Hits the Button- TipRanks. All rights reserved.
Fri, 04 Mar 2022 12:20 GMT Aurinia Pharmaceuticals (AUPH) Receives a Buy from Jefferies- TipRanks. All rights reserved.
Mon, 28 Feb 2022 21:28 GMT Aurinia Stock Takes a Hit, but Is It Warranted Analyst Weighs In- TipRanks. All rights reserved.
Copyright © 2016-2022 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
This could take some time, please wait.